Page last updated: 2024-11-12
ave 9488
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-fluoro-N-indan-2-yl-benzamide: nitric oxide synthase transcription enhancer that ameliorates portal hypertension [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10131276 |
| SCHEMBL ID | 248645 |
| MeSH ID | M0520895 |
Synonyms (18)
| Synonym |
|---|
| AKOS002332222 |
| n-(2,3-dihydro-1h-inden-2-yl)-4-fluorobenzamide |
| n-(2,3-dihydro-1h-inden-2-yl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide |
| ave-9488 |
| unii-9u46kwj9uf |
| 4-fluoro-n-(indan-2-yl)benzamide |
| 291756-32-6 |
| 9u46kwj9uf , |
| ave 9488 |
| benzamide, n-(2,3-dihydro-1h-inden-2-yl)-4-fluoro- |
| SCHEMBL248645 |
| 4-fluoro-n-(indan-2-yl)-benzamide |
| BOFMSBVSYVESTM-UHFFFAOYSA-N |
| 4-fluoro-n-(indan-2-yl) benzamide |
| n-(indan-2-yl)-4-fluoro-benzamide |
| 4-fluoro-n-indan-2-yl-benzamide |
| ave-308 |
| PD160567 |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "AVE 9488-treated rats had higher liver NOS-3 mRNA and protein levels, whereas NOS-3 mRNA and protein in the aorta and the SMA did not vary between groups." | ( Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Biecker, E; Heller, J; Hennenberg, M; Kang, A; Sauerbruch, T; Trebicka, J, 2008) | 1.29 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Reduced endothelial nitric oxide (NO) bioavailability contributes to the progression of heart failure." | ( Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Hoffmann, M; Ruetten, H; Thum, T; Tsikas, D; Widder, JD, 2008) | 0.35 |
| "Increased risk of thrombo-embolic events in congestive heart failure (CHF) has been attributed to a hypercoagulable state including vascular endothelial dysfunction and reduced bioavailability of nitric oxide (NO) as well as platelet activation." | ( Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer. Bauersachs, J; Eigenthaler, M; Ertl, G; Fraccarollo, D; Schäfer, A; Widder, J, 2009) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.09) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||